Novartis and Amgen halt trials into Alzheimer’s drug after patients get worse

pharmafile | July 12, 2019 | News story | Medical Communications Alzheimer's, Amgen, Banner Alzheimer's Institute, Novartis, dementia, pharma, research 

Novartis, Amgen and Banner Alzheimer’s Institute have dropped a study into investigational Alzheimer’s drug CNP520 (umibecestat) after some patient’s conditions worsened after taking the drug.

Amgen, Novartis and Banner Alzheimer’s Institute have discontinued two pivotal Phase 2/3 trials in the Alzheimer’s Prevention Initiative Generation Program after tests showed some patient’s cognitive functions had declined. The sponsors concluded that the potential benefits for participants did not outweigh the potential risks.

The decision comes as another disappointment in the area of Alzheimer’s research. CNP520 was being assessed for safety and efficacy in preventing or delaying the onset of Alzheimer’s in people at high risk of developing the disease.

Dr John Tsai, Head of Global Drug Development and Chief Medical Officer, commented: “Novartis has a strong research focus and commitment to patients. As researchers we have to accept today’s disappointing news as part of the search for innovative new treatments. We remain committed to advancing science in Alzheimer’s disease and continue to seek future solutions for people with neurodegenerative conditions.

“Beyond presenting our analyses, we will go a step further and will also share our data with the scientific community, not only to contribute to the increasing body of knowledge in Alzheimer’s research but to add value to ongoing discussions with governments, multilateral organizations, patient groups, pharmaceutical companies, and society, to ensure that we collectively address the public health challenges presented by this disease.”

Louis Goss

Related Content

BMS shares new research and development  plans at the company’s R&D day

Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Latest content